Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 391 to 400 of 432 total matches.

Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2 ...
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-4 |  Show IntroductionHide Introduction

Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
(Ibsrela - Ardelyx), a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for twice-daily oral treatment ...
The FDA has approved tenapanor (Ibsrela - Ardelyx), a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for twice-daily oral treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Tenapanor is the first NHE3 inhibitor to become available in the US.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):91-4 |  Show IntroductionHide Introduction

Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
, for intravenous treatment of complicated urinary tract and intra- abdominal infections in adults. Pronunciation ...
The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):31-3 |  Show IntroductionHide Introduction

Retapamulin (Altabax) - A New Topical Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008  (Issue 1280)
; Altabax – GlaxoSmithKline) is a topical antibiotic recently approved by the FDA for treatment of bullous ...
Retapamulin (re-tap'-a-mue'-lin; Altabax - Glaxo SmithKline) is a topical antibiotic recently approved by the FDA for treatment of bullous and non-bullous impetigo due to Streptococcus pyogenes and methicillin-susceptible Staphylococcus aureus. It is available as a 1% ointment by prescription only.
Med Lett Drugs Ther. 2008 Feb 25;50(1280):13-4 |  Show IntroductionHide Introduction

Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
:1524. 2. M Humbert et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary ...
The FDA has approved sotatercept-csrk (Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5   doi:10.58347/tml.2024.1702a |  Show IntroductionHide Introduction

Byvalson - A Beta Blocker/ARB Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 12, 2016  (Issue 1503)
blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only ...
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Med Lett Drugs Ther. 2016 Sep 12;58(1503):115-7 |  Show IntroductionHide Introduction

Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003  (Issue 1169)
by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Med Lett Drugs Ther. 2003 Nov 10;45(1169):90-2 |  Show IntroductionHide Introduction

Nemolizumab (Nemluvio) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease ...
Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):25-7   doi:10.58347/tml.2025.1722a |  Show IntroductionHide Introduction

Two New Oral Testosterone Products for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency ...
The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury caused by tumors, trauma, or radiation. Jatenzo, another oral testosterone undecanoate formulation, was approved for the same indication in 2019. No testosterone products are approved for treatment of low testosterone levels due solely to...
Med Lett Drugs Ther. 2022 Oct 31;64(1662):172-4 |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction